Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06333028 · ClinicalTrials.gov registry record
A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction
A clinical trial, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- 82
- Enrollment target
NCT06333028: Completed study, sponsored by Bausch & Lomb Incorporated.
NCT06333028 is a clinical trial that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06333028 has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
A Study to Evaluate the enVista® Aspire (EA) intraocular lens in Subjects Undergoing Cataract Extraction
Primary Outcome
Mean binocular best-corrected distance visual acuity (BCDVA) (logMAR) at Visit 1. Photopic BCDVA measured at 4 meters.
Interventions
- DEVICE enVista Aspire EA IOLs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2025-03-13 |
What the finished NCT06333028 record still lists
NCT06333028 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which enVista Aspire EA IOLs is the first listed.
NCT06333028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06333028 about?
NCT06333028 is a clinical study titled "A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction". A Study to Evaluate the enVista® Aspire (EA) intraocular lens in Subjects Undergoing Cataract Extraction
What is the current status of trial NCT06333028?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2024-05-30. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT06333028?
The interventions under investigation include: enVista Aspire EA IOLs (DEVICE).
Who is sponsoring clinical trial NCT06333028?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI